Trials / Completed
CompletedNCT01621542
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
Detailed description
Treatment with other WT1 vaccines in clinical trials has shown evidence of immunogenicity and clinical response in various malignancies. This study will assist with determining which dose level(s) to use in future clinical studies and will evaluate both clinical and immunological response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | WT2725 | WT2725 injection Study drug will be administered every 1-4 weeks |
Timeline
- Start date
- 2012-07-31
- Primary completion
- 2017-05-17
- Completion
- 2017-05-17
- First posted
- 2012-06-18
- Last updated
- 2019-07-17
- Results posted
- 2019-04-05
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01621542. Inclusion in this directory is not an endorsement.